MiNK Therapeutics (NASDAQ:INKT) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $9.00 price target on the stock.

MiNK Therapeutics Stock Up 1.6 %

Shares of MiNK Therapeutics stock opened at $0.85 on Tuesday. The stock’s fifty day moving average is $0.92 and its 200-day moving average is $0.94. The firm has a market capitalization of $29.47 million, a PE ratio of -1.41 and a beta of 0.07. MiNK Therapeutics has a 12-month low of $0.75 and a 12-month high of $1.90.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Analysts expect that MiNK Therapeutics will post -0.41 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC raised its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. 2.87% of the stock is currently owned by institutional investors and hedge funds.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.